ConductScience.org, home

Paper19877181

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.

Vitale A and 7 others. Hepatology, 2010. Cited by 91 papers, by iCite.

Cite this record

ConductScience Library. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Papers, record 19877181. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19877181

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
PubMed
Journal
Hepatology
PubMed
Year
2010
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
91
iCite
Relative citation ratio, by iCite
2.43
iCite
Revised in PubMed
2018-12-01
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vitale AAlessandro
2Volk MLMichael L
3Pastorelli DDavide
4Lonardi SSara
5Farinati FFabio
6Burra PPatrizia
7Angeli PPaolo
8Cillo UUmberto

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
BenzenesulfonatesMajor topic
Carcinoma, HepatocellularMajor topic
PyridinesMajor topic
Cost-Benefit Analysis
Humans
Liver Transplantation
Markov Chains
Models, Theoretical
Monte Carlo Method
Niacinamide
Phenylurea Compounds
Quality-Adjusted Life Years
Sorafenib
Treatment Outcome
Waiting Lists

Source PubMed

Download CSV of topics

Comments and corrections4

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in20034046Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models.https://conductscience.org/library/papers/20034046PubMed
Comment in20041410Hepatocellular carcinoma: sorafenib before liver transplantation?https://conductscience.org/library/papers/20041410PubMed
Comment in20812364Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.https://conductscience.org/library/papers/20812364PubMed
Comment in22127280Sorafenib use while waiting for liver transplant: we still need to wait.https://conductscience.org/library/papers/22127280PubMed

Download CSV of comments and corrections

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.

PMIDTitleJournalYearIn PapersSource
41104208Neoadjuvant systemic therapy for hepatocellular carcinoma: challenges and opportunities-a narrative review.Hepatobiliary Surg Nutr2025https://conductscience.org/library/papers/41104208PubMed
38627031British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.Gut2024https://conductscience.org/library/papers/38627031PubMed
37077517Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy.World J Gastroenterol2023https://conductscience.org/library/papers/37077517PubMed
36498435The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile.Int J Environ Res Public Health2022https://conductscience.org/library/papers/36498435PubMed
36438781Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation.Transpl Int2022https://conductscience.org/library/papers/36438781PubMed
36068876Neoadjuvant Therapy for Hepatocellular Carcinoma.J Hepatocell Carcinoma2022https://conductscience.org/library/papers/36068876PubMed
35368665A Novel Prognostic Model for Identifying the Risk of Hepatocellular Carcinoma Based on Angiogenesis Factors.Front Genet2022https://conductscience.org/library/papers/35368665PubMed
35222709Combination treatment with sorafenib and wh-4 additively suppresses the proliferation of liver cancer cells.Exp Ther Med2022https://conductscience.org/library/papers/35222709PubMed
34631511Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection.Front Oncol2021https://conductscience.org/library/papers/34631511PubMed
34400051Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.HPB (Oxford)2022https://conductscience.org/library/papers/34400051PubMed
34358718National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.Clin Gastroenterol Hepatol2022https://conductscience.org/library/papers/34358718PubMed
32399593Recommendations for medical care of oncological patients during the COVID-19 epidemic: experiences from China.Updates Surg2020https://conductscience.org/library/papers/32399593PubMed
31573053Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.Pharmacoeconomics2020https://conductscience.org/library/papers/31573053PubMed
31391767Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.World J Gastroenterol2019https://conductscience.org/library/papers/31391767PubMed
31185950A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.BMC Cancer2019https://conductscience.org/library/papers/31185950PubMed
30840163Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.Dig Dis Sci2019https://conductscience.org/library/papers/30840163PubMed
30190965Liver transplantation for hepatocellular carcinoma: how far have we come and what is the future?Hepat Oncol2014https://conductscience.org/library/papers/30190965PubMed
29804373[The mechanism and current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation].Zhonghua Gan Zang Bing Za Zhi2018https://conductscience.org/library/papers/29804373PubMed
29467861Induction of apoptosis by an oleanolic acid derivative in SMMC-7721 human hepatocellular carcinoma cells is associated with mitochondrial dysfunction.Oncol Lett2018https://conductscience.org/library/papers/29467861PubMed
28799575Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.Adv Radiat Oncol2016https://conductscience.org/library/papers/28799575PubMed

See all 34 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19877181

GET https://conductscience.org/api/papers/v1/19877181/cited_by?page=2